Molecular signaling and targets from itch: lessons for cough
Pamela Colleen LaVinka1* and Xingzhong Dong1,2*

Abstract
Itch is described as an unpleasant sensation that elicits the desire to scratch, which results in the removal of the irritant from the skin. The cough reflex also results from irritation, with the purpose of removing said irritant from the airway. Could cough then be similar to itch? Anatomically, both pathways are mediated by small-diameter sensory fibers. These cough and itch sensory fibers release neuropeptides upon activation, which leads to inflammation of the nerves. Both cough and itch also involve mast cells and their mediators, which are released upon degranulation. This common inflammation and interaction with mast cells are involved in the development of chronic conditions of itch and cough. In this review, we examine the anatomy and molecular mechanisms of itch and compare them to known mechanisms for cough. Highlighting the common aspects of itch and cough could lead to new thoughts and perspectives in both fields.

Keywords: Itch, Cough, Skin, Airway, C-fibers, A-fibers, Mast cells, TRPs, GPCRs, Inflammation

Introduction
Over 350 years ago, the German physician Samuel Haffenreffer defined itch, or pruritus, as an “unpleasant sensation that elicits the desire or reflex to scratch.” Why is such an unpleasant sensation needed? Itch causes the protective mechanism of scratching. The physical act of scratching dislodges the irritant, such as an insect or poisonous plant, from the skin. Therefore itch results in the removal of a harmful stimulus. Scratching may not just be protective though. The actual act of scratching can result in mechanical pain, which helps to suppress the unpleasant itchy sensation [1,2]. Therefore scratching can both help remove an irritant and try to suppress the itch resulting from it.

Although the skin is the primary site for the generation of itch, itchiness can also be felt in mucosal surfaces. So perhaps itch is felt in the airway and since we cannot scratch our airway, it is reasonable to think that the main response to airway itch would be to cough. Coughing helps to clear irritants and evoke itch-suppressing mechanical pain in the airway, similar to scratching itchy skin. Coughing is most easily evoked from stimulation of the larynx, trachea, and larger bronchi and many types of stimuli can result in cough, not just itch [3]. The cough reflex results in the removal of foreign material from the large bronchi with successive coughs forcing the foreign material or secretion through the smaller bronchi towards the trachea so the irritants can be expelled [4,5].

In this review, we will talk about the mechanisms of itch and cough and the similarities found between the pathways. The parallels between itch and cough can perhaps lead to new perspectives and ideas in ways to test the respective pathways and how they may possibly work.

Review
Primary sensory fibers of itch and cough pathways
Before looking at the specifics of a sensory system, we should first look at the basic anatomy that transmits the sensory information. Figure 1 illustrates sensory fibers that are primarily responsible for itch and cough. Primary sensory neurons in dorsal root ganglia (DRG) play an essential role in generating itch by detecting itch stimuli through their peripheral axons in the skin and sending signals to the spinal cord via their central axons [6]. In the cough pathway, the cough sensory afferent...
fibers terminate in or under the airway epithelium with their cell bodies located in the vagal nodose or jugular ganglia [4]. The nodose ganglia are embryologically derived from the epibranchial placodes while the jugular ganglia originate from the neural crest [7]. Interestingly, the DRG sensory neurons also originate from the neural crest [8]. Sensory neurons that play a role in itch or cough can be classified into two distinct fibers, the thinly myelinated A\textsubscript{\textdelta}-fiber and the unmyelinated C-fiber.

**Myelinated A\textsubscript{\textdelta}-fibers**

**Itch** In early investigations into itch, it was suggested that there were two subjective components to itch. First a ‘pricking’ itch was felt, followed by a ‘burning’ itch. The ‘pricking’ itch was sensed via the myelinated sensory fibers and abolished when these myelinated fibers were blocked [9]. It has been shown in studies involving the known pruritogen cowhage (Mucuna pruriens), that mechanosensitive A\textsubscript{\textdelta}-fibers play a role in itch. Cowhage causes intense itching when injected into the skin [10]. Psychophysical human studies show decreased itch from cowhage upon blocking of myelinated A fibers. In monkeys, cowhage activates mechanosensitive A fibers while some mechanoinensitive A fibers are activated by another pruritogen, histamine [11].

**Cough** Myelinated A\textsubscript{\textdelta}-fibers play a role in the generation of cough. The A\textsubscript{\textdelta}-fibers are responsible for the violent, sudden cough that occurs upon aspiration [12]. These myelinated vagal afferent cough fibers are sensitive to acid and mechanical stimulation but are relatively insensitive to capsaicin and the effects of anesthesia [13]. In dogs, when myelinated nerve conduction is blocked by vagal cooling, mechanically and chemically stimulated cough is inhibited [14]. Single fiber vagal recordings of afferent A\textsubscript{\textdelta}-fibers in the guinea pig trachea activate upon exposure to known cough-evoking hypotonic, hypertonic, and low-chloride stimuli [15]. Vagal A\textsubscript{\textdelta}-fibers also show sensitivity to very low levels of touch stimulus, which can trigger cough [16].

Different types of A\textsubscript{\textdelta}-fibers are involved in the regulation of breathing and cough. These different myelinated vagal sensory fibers include rapidly adapting receptors (RARs), slowly adapting receptors (SARs) and the cough receptors. The RARs and SARs are differentiated on their ability to adapt to lung inflation, either rapidly or slowly [17-19]. RARs and SARs are thought to play a modulatory, synergistic role in the cough reflex but are not responsible for initiating cough [13,20]. The myelinated vagal fiber thought to be responsible for initiating cough is the touch sensitive A\textsubscript{\textdelta}-fiber or cough receptor. The cough receptor cell bodies are mostly located in the nodose ganglia with axons terminating in a circumferential pattern between the epithelium and smooth muscle in the mucosa of the guinea pig trachea [21]. The cough receptors are very sensitive to punctate mechanical stimuli and changes in pH in conscious and anaesthetized animals [22]. Up till recently, the cough receptor was included in the RAR fibers, until Canning et al. distinguished this subset in their 2004 paper. Cough receptors have several unique qualities that discriminate them from being classified as RARs or SARs. Cough receptors do not show a response to changes in lung volume like RARs and SARs and are primarily located in the extrapulmonary airways, rather than the intrapulmonary airways [22]. These afferent myelinated fibers project to the trachea via the recurrent laryngeal nerves and when these nerves are cut, coughing is abolished [22].

**Figure 1 Primary sensory neurons of itch and cough.** A. Itch is primarily sensed through the epithelium by unmyelinated C-fibers, whose cell bodies are in the dorsal root ganglion. Degranulation of mast cells release inflammatory mediators that can activate C-fibers, which secrete neuropeptides, such as Substance P. Secretion of Substance P results in inflammation and vasodilatation, which sensitizes nerves. B. Cough results from activation of myelinated cough receptors and unmyelinated C-fibers, whose cell bodies are in the jugular and nodose ganglia. Extensive C-fiber endings are found under the airway epithelium while cough receptors endings terminate in the mucosa between the epithelium and smooth muscle. Degranulated mast cells release mediators that activate C-fibers, causing release of Substance P. Substance P release results in inflammation, vasodilatation and sensitization of nerves.
nodal vagal afferent fibers conduct action potentials at
3–5 m/s and lack TRPV1 receptors, which is why they
are relatively insensitive to capsaicin [22,23].

The role of myelinated fibers in cough is much more
defined and explored when compared to myelinated fi-
bers’ role in itch. What is interesting in both is that
these myelinated fibers are not solely responsible for
the genesis of itch or cough. The myelinated A-fibers
interact with unmyelinated C-fibers to respond to irri-
tating stimuli, resulting in itch or cough. In the skin,
coughing causes itch through activation of both mye-
linated and unmyelinated fibers [11,24]. In the airway,
activation of C-fibers results in many of the same re-
flexes (cough, bronchoconstriction) as activation of
myelinated fibers, so the reflexes are likely a result of
both types of sensory fibers [25]. In both itch and
cough, C-fibers play a role in setting the threshold,
controlling the sensitivity of the system.

C fibers

Itch Itch is primarily mediated by slower conducting
C-fibers innervating the dorsal horn of the spinal cord.
Early itch studies used spicules of cowhage to show
that the strongest itch is felt in the dermo-epidermal
juncture area, the area where unmyelinated sensory fi-
bers innervate [10,26]. Five percent of the C-fibers in-
nervating the skin react to puritogenic application,
with distinct populations of C-fibers corresponding to
itch in individual nerve C-fiber recordings in humans
[24,27]. Itch sensing C-fibers slowly conduct action po-
tentials (0.5 m/s) and innervate large territories of skin
[27]. When C-fibers are desensitized with pretreatment
of capsaicin, itch is greatly reduced or blocked [28].

However, not all C fibers respond equally to all pruritogens. C-fibers can be divided into subcategories
according to their response to various stimuli and
these subcategories respond differently to different
pruritic stimuli. C-fibers classified as mechanical and
heat responsive (CMH) have been shown to respond
to cowhage and histamine [29]. Mechanically-insensitive
C-fibers that respond to histamine (CMiHis+) have a
preferential, not exclusive, activation to pruritic sub-
stances such as histamine and prostaglandin E(2) (PGE2)
and substances that activate more of these specific
CMiHis+ fibers are considered more potent pruritic
agents [19]. Microneurography recordings of C-fibers
in human volunteers show that cowhage activates
mechanosensitive C-fibers while histamine activates
mechano-insensitive units. Capsaicin activates fibers in
both classes [24]. So cowhage induces itch through a dif-
ferent set of C-fibers than histaminergic itch. The acti-
vation of two different subsets of C-fibers shows that
there are multiple pathways for pruritus, changing
according to the stimulus.

Cough C-fibers are also involved in the generation of
cough. It is thought that C-fibers are important to a sec-
type of cough, which is used to get rid of an itchy
feeling in one’s throat. This feeling is more typical of
chronic cough [12]. Cough is generated when vagal
C-fibers and myelinated cough receptors are activated
[20]. The C-fibers form a loose network in the airway mu-
cosa with branches found in deeper lung structures [7].
The majority of C-fibers innervating the airway arise
from the vagus nerve, however there is also some innervation
by spinal afferent C-fibers whose cell bodies are in the
DRG [30]. There are two sets of vagal C-fibers, the bron-
chial C-fibers which innervate the large airways and the
pulmonary C-fibers which innervate the smaller, peri-
pheral lung tissue [30]. Collectively these C-fibers are the
bronchopulmonary C-fibers and can be activated using a
variety of chemical stimuli, including capsaicin, bradykinin
and protons. Inhalation of these chemicals such as capsa-
icin in humans causes an itchy feeling in the airway and
evokes cough [12,20,31,32]. In single fiber recordings, all
vagal C-fibers tested respond to capsaicin and capsaicin-
sensitive C-fibers are found in both the nodose and jugu-
lar ganglion [7,16]. However, in dogs and rats, rapid shal-
low breathing is caused by C-fiber activation, but not
cough, showing that there can be species differences
[3,14,33]. In fact, C-fiber activation can inhibit mechani-
cally induced cough [14]. These inhibitory C-fibers are
thought to be the C-fibers with cell bodies in the nodose
ganglion. Indeed, activation of nodose C-fibers with ad-
enosine reduce citric acid evoked cough [20]. This implies
that the jugular ganglia C-fibers are the ones playing an
excitatory role in cough. The differences seen in C-fibers
originating from the nodose ganglia versus C-fibers origi-
nating from the jugular ganglia are evidence of a multi-
faceted cough reflex with many ways to fine-tune a re-
response. However, the fact that many C-fiber activators
cause cough in awake guinea pigs and humans, speaks to
their role in generating cough.

Anatomically, the chemosensitive C-fibers extend nu-
merous terminals superficially into the airway epithelium,
placing them in an ideal position to react to inhaled che-
mary agents [34]. Labeling studies in guinea pigs show
C-fibers terminating underneath the airway epithelium,
with swelling suggestive of the presence of synaptic vesi-
cles filled with Substance P (SP), Calcitonin gene related
peptide (CGRP) and Neurokinin A [21]. When the fibers
innervating the tracheal epithelium are analyzed, nearly all
C-fibers have cell bodies in the jugular ganglion and 60%
are containing fibers [32,35]. These jugular C-fibers pro-
mote coughing [20]. No peptide positive fibers are found
in the nodose ganglion [32,36]. So within the C-fibers
there are two subsets, peptidergic (in jugular ganglion)
and non-peptidergic (in nodose ganglion) [37]. However,
the C-fibers that innervate the lungs (below the trachea)
originate from both ganglia, with over 60% of C-fibers in the lungs found in the nodose ganglion [7].

Many argue that direct cough is caused by the touch sensitive Aδ-fibers and that C-fibers cause cough by indirect mechanisms. This is shown by C-fiber evoked cough’s sensitivity to anesthesia. Anaesthetized animals often do not cough upon application of C-fiber stimulants but cough when awake. Stimulation of bronchopulmonary C-fibers with chemical stimuli can result in bronchoconstriction and mucous production, both of which can cause cough [38]. Stimulated C-fibers release which mediates nitric oxide and results in an increase in fluid in airways, activating RARs and causing cough [39]. It was found that pre-treatment with a C-fiber stimulant, while not evoking cough alone, decreased the cough threshold for RAR and cough receptor stimulation. Conversely, desensitizing C-fibers with capsaicin application, led to a decrease in coughing upon myelinated cough fiber activation [40]. These findings suggest a synergistic central interaction between C-fibers and myelinated RARs and cough receptors.

With the knowledge that C-fibers are involved in both itch and cough, it is likely that there are similarities to be found in activation of these sensory neurons. Large territories of innervation by C-fibers are seen in both the skin and lung. The jugular ganglion is derived from the neural crest, just like the dorsal root ganglion. With similar embryonic starts, these fibers may share many characteristics. Neural crest derived vagal nerves are seen innervating the large extrapulmonary airways while placodal nerves are seen innervating deeper lung tissue leading to speculation that the more superficial neural crest derived vagal nerves are responsible for reacting to external environmental stimuli [7,37]. This parallels the more superficial termination of C-fibers in the skin that are thought to be responsible for itch [41].

Knowing that itch and cough are mediated by similar sensory neurons, the specifics of activating these fibers can be examined and compared. Two types of receptors are activated on sensory fibers, ionotropic and metabotropic. In both of these categories, itch and cough work through the same receptors in multiple instances. Table 1 lists some of the known pruritic and tussive agents and modulators as well as their pathways.

**Table 1 Activators and modulators of itch and cough pathways**

| Agent       | Pathway     | Evoke Itch       | Evoke Cough     |
|-------------|-------------|------------------|-----------------|
| Bradykinin  | B1, B2      | Weakly, modulator| Yes, modulator  |
| Capsaicin   | TRPV1       | superficial, modulator | Yes            |
| Oxidative   | TRPA1       | Yes              | Yes, modulator  |
| Cowhage     | PAR2, PAR4  | Yes              | Yes             |
| Histamine   | H1, H4      | Yes, modulator   | Modulator       |
| Proteases   | PAR1, PAR2, PAR4 | Yes | Modulator     |
| Serotonin   | SHT2, SHT3  | Yes              | Modulator       |
| Substance P | NK1, NK2    | Yes              | Modulator       |

**Ionotropic receptors of itch and cough**

**TRPV1**

**Itch** The transient receptor potential, vanilloid 1 (TRPV1) receptor is a membrane bound, ligand gated channel. It is a six transmembrane spanning protein that undergoes a conformational change upon binding of a ligand, allowing cations into the nerve and resulting in activation of primary sensory neurons [42]. The role of TRPV1 has often been explored using one of its most famous ligands, capsaicin. If capsaicin is applied in a punctuate manner to the epidermis, it causes itch [43]. TRPV1 are expressed on a subset of C-fibers and repeated application of capsaicin will desensitize these C-fibers. Desensitizing C-fibers help reduce the itch induced by histamine [28]. When TRPV1 receptors were blocked by capsazepine, histamine evoked currents were reduced in sensory neurons. Similarly, histamine failed to activate TRPV1−/− neurons [44]. Therefore, TRPV1 plays an important role in histamine-dependent itch. Mice deficient in Pirt, a TRPV1 modulator, have decreased scratching in response to histamine, chloroquine, and ET-1, implicating TRPV1 as an important component in multiple itch pathways [45].

While TRPV1 can be directly activated by capsaicin, its main role is functioning downstream of many pruritogens. Pruritogens activate G protein coupled receptors (GPCRs) that result in intracellular cascades that can activate TRPV1 [44,46]. GPCR activation results in production of phospholipase C (PLC) beta3, an intracellular mediator that activates TRPV1 upon histamine application [44]. PLCbeta3 also mediates serotonin-evoked itch [46]. TRPV1 can also be activated by diacylglycerol (DAG) which is produced when PIP2 is hydrolyzed by PLC [46,47]. Expression of TRPV1 and phosphorylated TRPV1 receptors increase in atopic dermatitis (AD) mouse models lesions [48]. TRPV1 contributes to skin inflammation by causing release which leads to upregulation of SP’s receptor, neurokinin 1 (NK1). Increased levels of NK1 expression is seen in lesions from AD models [48,49]. Blocking TRPV1 stops the upregulation of NK1 receptors and decreases bouts of scratching [48].

**Cough** TRPV1 is also thought to be a strong effector of the cough reflex in response to many different stimuli [50]. TRPV1 is found in both vagal ganglia as well as throughout the airway [51,52]. Airway mucosal biopsies
from patients suffering from chronic cough showed a fivefold increase in TRPV1 expression [53]. Capsaicin is a commonly used tussive agent and resiniferatoxin, a strong TRPV1 agonist, causes cough by direct activation of TRPV1 [54]. PGE2 and bradykinin, which are known to cause cough, depolarize vagal sensory neurons through activation of TRPV1 [50]. Itch has been recently shown that oxidative stress is involved in diseases causing chronic itch [63]. This is important as oxidative stress is involved in diseases causing chronic itch [63].

### Inflammatory mediators

Activation of TRP channels leads to release of inflammatory neuropeptides from C-fibers. These neuropeptides include the tachykinins (Substance P, neurokinin A, neurokinin B) and calcitonin gene related peptide (CGRP) [71]. Other inflammatory chemicals, such as bradykinin, may also be released. Neurogenic inflammation has been shown to play roles in both chronic itch and chronic cough.

### Substance P

**Itch** Application of SP to the skin in humans causes itch which is prevented by antihistamines and so is thought to be histamine dependent [72]. This collaborates with the fact that depleting mast cells, a primary source of histamine, with compound 48/80 decreased the itching, wheal and flare response from SP intradermal injections in human volunteers [73]. Substance P is thought to mediate itch through activation of the neurokinin (NK) receptors. After skin-scratching stimulation, NK1 is up-regulated in the epidermal keratinocytes and Substance P is depleted from sensory fibers, indicating secretion of SP into the surrounding cells [74]. It was found that NK1 antagonists inhibit scratching in a dermatitis model [75]. Clinically, patients with chronic pruritus have reduced itching upon using a NK1 antagonist [76].

### Cough

**Application of bradykinin to the skin in humans causes itch which is prevented by antihistamines and so is thought to be histamine dependent [72].** This collaborates with the fact that depleting mast cells, a primary source of histamine, with compound 48/80 decreased the itching, wheal and flare response from SP intradermal injections in human volunteers [73]. Substance P is thought to mediate itch through activation of the neurokinin (NK) receptors. After skin-scratching stimulation, NK1 is up-regulated in the epidermal keratinocytes and Substance P is depleted from sensory fibers, indicating secretion of SP into the surrounding cells [74]. It was found that NK1 antagonists inhibit scratching in a dermatitis model [75]. Clinically, patients with chronic pruritus have reduced itching upon using a NK1 antagonist [76].

**Application of bradykinin to the skin evokes feelings of weak itch and pain in healthy skin. However, pruritic inflammation can change the effect of bradykinin. If bradykinin is applied to itchy inflamed skin, like lesions in AD patients, much more intense itch is felt. Itch evoked by bradykinin is histamine-independent [72]. When inflammation is induced by complete freunds adjuvant (CFA), subsequent application of bradykinin causes robust scratching. This behavior is mediated by the kinin B1 receptor [82].** Both kinin...
receptors, B1 and B2, are shown to contribute to itch. This is proven by the reduced scratching of B1 and B2 knockout mice to different pruritic stimuli. B1 and B2 antagonists have similar effects [83]. Data suggests that pruritic responses are mediated mostly by B2 receptors. Antagonists of kinin (B1 and B2) receptors help reduce itch from PAR2 agonists, implying that kinin receptors are activated downstream from PAR2 and can mediate protease evoked itch also [83]. It has been shown that patients taking angiotensin converting enzyme (ACE) inhibitors for hypertension, occasionally suffer from pruritus as a side effect [84]. ACE inhibitors lead to increased levels of bradykinin, as ACE degrades bradykinin usually. The increased levels of bradykinin are thought to cause the pruritus, which is usually a precursor to a much more dangerous side effect, angioedema [84,85].

Cough Bradykinin is endogenously produced, with airway inflammation causing an increase in levels [86]. Bradykinin can depolarize human, guinea pig and mouse vagal afferents, activating C- and Aβ-fibers in the jugular ganglion as well as nodose C-fibers [50,87]. In humans, bradykinin causes cough and bronchoconstriction [88,89]. Bradykinin also evokes cough in guinea pigs [16]. Activation is thought to occur through the B2 receptors in the guinea pigs and humans but the B1 receptor is also involved in mice, showing species differences [16,50,87]. B2 receptors are found in the vagal nodose ganglion of rats and humans [90]. Bradykinin is also implicated in sensitizing the cough reflex, enhancing cough response to citric acid [78]. Patients taking ACE inhibitors (which normally degrades bradykinin) often develop chronic cough [91]. In fact, patients often stop taking the ACE inhibitor due to the chronic cough that develops. Bradykinin's tussive effects are tied to activation of TRPV1 and TRPA1. Bradykinin's activation of B2 receptors works through the Gq/11 transducer, which results in PLC and possible stimulation of TRPV1 [92,93]. Antagonists of either channel alone partially inhibited in vivo and in vitro responses of vagal neurons to bradykinin. Applying a TRPV1 antagonist along with a TRPA1 antagonist completely prevented the effects of bradykinin [50].

Mast cell mediators
Mast cells are found in close contact to nerves, allowing them to easily affect sensory perception [94]. Mast cells play important roles in both itch and cough, especially in chronic conditions. Scratching the skin of mice causes significant mast cell degranulation within minutes [74]. In atopic dermatitis mouse models, increased levels of degranulated mast cells are found [48]. In patients diagnosed with chronic nonproductive cough (CNPC), bronchoalveolar lavage (BAL) showed increased numbers of inflammatory cells and airway inflammation when compared to controls [95]. Elevated levels of mast cells were found in BAL samples in patients with chronic cough [96]. Upon activation, mast cells degranulate and release biologically active mediators. These mediators include histamine, serotonin, and proteases [97]. We will discuss the roles of these mast cell mediators in itch and cough below.

Histamine
Itch It is well established that introduction of histamine to human skin causes itch [98,99]. Histamine also evokes scratching in a dose-related manner in mice [100]. Spinothalamic neurons that respond to itch-evoking histamine but not pain-evoking mustard oil were found in the cat, implicating an itch specific pathway [101]. The similarities and differences between itch and pain have been discussed in other reviews and will not be covered here [41].

Histamine is naturally produced by the body from the amino acid histidine, with mast cells being one of the main sources of histamine in the body [102,103]. There are four subtypes of histamine receptors, H1-H4 [104]. The H1 receptor plays a starring role in evocation of itch via histamine [105]. Antihistamines that block the H1 receptor have proven helpful in the treatment of urticaria (hives), decreasing itching and reducing size of wheals and flares [102]. Histamine receptors are GPCRs, activating an intracellular signaling network that results in activation of ionotropic receptors, producing an action potential. Therefore, histamine evokes currents only when the H1 receptor is coexpressed with the ionotropic TRPV1 receptor [44]. The H1 receptor is coupled with Gq proteins and activates PLC [106]. Specifically H1 receptors are mediated through PLCβ3, which activates TRPV1 [44,107]. Histamine is also shown to activate TRPV1 via PLA2 [44]. Inhibiting PLA2 stops histamine-induced Ca2+ influx in sensory neurons [108]. H4 receptors are also implicated in itch. Histamine causes itching in atopic dermatitis through activation of the H4 receptor [102]. Patients with AD are also more sensitive to histamine, showing increased responses in their skin lesions [109]. H4 agonists cause scratching upon injection and H4 antagonists decrease itching and inflammatory and pruritic symptoms in AD mouse models [110-112].

Cough Histamine also plays an important role in modulating cough sensitivity. Histamine does not directly cause cough as its application does not result in action potentials in guinea pigs’ isolated vagal preps [16,32]. In fact, application of histamine to vagal nodose neurons only results in a small membrane depolarization [113]. However, histamine does sensitize vagal bronchopulmonary C-fibers’ response to capsaicin and mechanical stimulation [114]. Antagonizing
histamine via the H1 receptor significantly attenuated citric acid evoked cough [115]. Causing increased cough sensitivity can lead to chronic cough and chronic cough sufferers do have elevated levels of histamine in their sputum and lungs [96,116]. Eosinophilic bronchitis, a disease often causing chronic cough, increases levels of histamine in patients’ sputum [117]. Human studies using ultrasonically nebulised distilled water (UNDW) to evoke cough show reduced UNDW responses when loratadine, an H1 antagonist, is given to patients suffering from chronic dry cough. This reduction implicates a role for histamine in chronic cough conditions [118].

Serotonin
In rodents, a main source of serotonin is mast cells [119]. While human mast cells can synthesize and secrete serotonin and may do so in inflammatory conditions, this is not thought to be the primary source of serotonin [120]. Serotonin can be found in platelets and neuroepithelial bodies, which are innervated by vagal sensory neurons, in the airway and thus still play a role in cough evocation [121,122].

Itch
Serotonin (5-HT) causes scratching when injected into the faces of rats [123]. Topically applying serotonin to the back of rats also results in scratching and activates DRG neurons [124]. Mice also scratch in a dose-related manner to 5HT [100]. In a dry skin chronic itch model, a 5HT antagonist (ketanserin) significantly decreases bouts of scratching in mice [125]. This implies a role for 5HT in chronic itch and patients suffering from eczema and psoriasis do show increased expression of 5HT [126,127]. However, in human studies, injection of 5HT causes mixed feelings of itch and pain. The mixed sensations are felt through activation of a subset of cutaneous C fibers [128]. Itching from intradermal 5HT injections is thought to be partially mediated by the metabotropic 5-HT2 receptor as agonists of this receptor induce scratching and antagonists reduce scratching [129]. The ionotropic 5-HT3 receptor may also play a role in itch as antagonists of the 5-HT3 receptor may be effective in treatment of opioid-induced pruritus [130].

Cough
Serotonin stimulates respiratory reflexes [131]. In dogs, phenylbiguanide, a 5HT receptor agonist, activates bronchial C-fibers [132]. Nodose ganglia C-fibers respond to serotonin [93]. Specifically, serotonin activates the ionotropic serotonin receptor 5HT3 in rabbit nodose ganglion neurons [133,134]. Triggering 5HT3 receptors leads to membrane depolarization of most small diameter neurons in the vagal ganglia [135]. The guinea pig also shows activation of the 5HT3 receptor on intrapulmonary nodose C-fibers [93]. Interestingly, the jugular ganglion C fibers in guinea pigs do not respond to 5HT [136]. However, 5HT does stimulate jugular ganglion C fibers in mice, possibly through a metabotropic 5HT receptor [137]. It is possible the metabotropic 5HT2A receptor might be involved, because in mouse tracheal preps, serotonin causes tracheal muscle contraction via the 5HT2A receptor [119]. This contrasts with activation of the nodose C fibers of mice, which is mediated by the ionotropic 5HT3 receptor [137].

Proteases
Itch
Endogenous serine proteases, including trypsin and trypsin, cause itch by activation of the Protease activated receptor (PAR) family. These GPCRs are activated when cleavage of the NH2 terminus of the PAR receptor results in a tethered self-activating ligand [138]. There are four members of the PAR family, PAR1-4 [139]. PAR2 is involved in itch. PAR2 is a seven-transmembrane GPCR that is proteolytically activated by trypsin and the agonist SLIGRL [140]. When SLIGRL is injected into the skin of mice, robust scratching is shown [141,142]. SLIGRL activation of PAR2 releases PGE2 from keratinocytes, whose secretion enhances scratching behavior [143]. DRG neurons show PAR2 cells that coexpress with Substance P and CGRP. When mast cells release tryptase, it activates PAR2. PAR2 activation results in release of the coexpressed neuropeptides, causing inflammation [144]. This activation cascade is thought to play a role in trypsin induced scratching as well. Tryptsin activates PAR2 on mast cells, which results in release of SP and CGRP and scratching. Data supports this by showing depletion of mast cells prevented trypsin induced scratching [145]. In chronic itch conditions such as atopic dermatitis, increased expression of PAR2 was found on primary afferent sensory nerves as well as increased levels of tryptase [146]. Dry skin mouse models exhibited sensitization to PAR2 agonists and a PAR2 antibody helped reduce scratching [125]. PAR2 itch and neuron sensitization is thought to occur through interaction with TRP channels, like TRPV1. Deletion of TRPV1 or introduction of a TRPV1 antagonist prevents scratching from trypsin injection [145]. PAR2 has also been shown to coexpress with TRPV4 and TRPA1 [147,148]. PAR2 pathways are histamine independent because antihistamines did not help reduce itch in atopic dermatitis or mice injected with SLIGRL [141,146]. PAR4 has also been shown to elicit scratching in mice upon activation [100]. PAR2 and PAR4 work through the G protein and Ca2+ signaling [27]. The active component in cowhage, mucunain, has been shown to be a ligand for PAR4 in addition to PAR2 [149].

Cough
Proteases and their receptors also play a role in cough and airway inflammation. In vagally innervated
Gastrin-releasing peptide (GRP) is the mammalian homologue of the amphibian neuropeptide bombesin. GRP was found on peptidergic unmyelinated small to medium sized DRG neurons with 80% of GRP+ neurons also expressing TRPV1 receptors [142]. In GRPR knockout mice, scratching from histamine, SLIGRL and chloroquine induced itch was reduced [142]. GRPRs are found in lamina I of the dorsal horn and when an GRPR agonist was injected intrathecally, bypassing peripheral activation of the skin, scratching was exhibited, supporting the idea of GRPR cells being itch specific [142]. When GRPR spinothalamic cells were ablated using bombesin-saporin, reduction of scratching from pruritogenic (both histamine-dependent and histamine-independent) stimulation was practically extinguished [159]. This included scratching induced by 5HT and compound 48/80, a mast cell degranulator.

Cough Bombesin induces bronchoconstriction in guinea pigs airways, an effect that is absent if the trachea or bronchi was stripped of its epithelium [66]. In rats, GRP and bombesin exposure cause an increase in rapid, shallow breathing characteristic of activation of C-fibers. In fact, GRP and bombesin increase the pulmonary chemoreflex response to capsaicin. This potentiation is blocked when pulmonary C-fiber conduction is not allowed [160]. All three types of bombesin-like peptide receptors are found in human lung tissue, specifically in human bronchial epithelial (HBE) cells [161]. Having the receptors located in the airway epithelium, close to where C-fibers terminate, implies that GRP could play a regulatory role on the C-fibers involvement in the cough reflex.

Conclusions and future directions

The field of itch research has only started to be explored, with much expansion seen over the last couple of years. There are still many challenges that need to be overcome in the itch field. Recently, many novel itch receptors and pruritogens have been identified, however, our knowledge on how they function or mis-function during chronic itch conditions is still limited. Is there a common downstream factor which is required for most, if not all, itch signaling pathways? If such a factor is discovered, it will most likely be found using animal studies. Therefore as our knowledge of itch expands, these findings should also be validated in human studies. This will require extensive collaboration between basic researchers and clinicians, eg dermatologists, which can be logistically difficult. Another challenge is that while most major pharmaceutical companies are developing antipain drugs, many companies do not realize that chronic itch is a major clinical problem. Without industrial collaboration, it is difficult for basic research laboratories to conduct large scale screens to identify itch blockers. Pharmaceutical companies need to be convinced that...
development of anti-chronic itch drugs will have large market values.

As our anatomical knowledge of itch grows, it is obvious that the sensory Aδ- and, more importantly, C-fibers play a pivotal role in itch perception. Tied closely to activation of these sensory fibers is neurogenic inflammation, which involves release of inflammatory agents like SP and bradykinin as well as products of mast cells, all of which result in itch, flares, wheals, and can easily become chronic conditions. All of these individual factors also play roles in cough and the similarities between itch and cough in sensing irritants from environment can be seen. Cough has an additional factor to incorporate though, movement. While the end result of itch is scratching, the muscles and joints being used to scratch are not receiving signals directly from the itching skin. With cough, smooth muscle movement is incorporated into the actual cough reflex in order to move the irritant or blockage up the airway and out. It is this additional motility aspect that could result in more specialized involvement of myelinated fibers in cough, a specialization not needed in itch. Chronic cough is one of the most common reasons to visit the doctor and like chronic itch, can quickly become detrimental to quality of life [162]. Realizing the similarities between itch and cough can lead to new ideas and even perhaps, new ways to apply existing medications to new conditions.

Clinically, anti-histamines are often prescribed and have been shown to help with itch and cough. However, by no means do anti-histamines help with all conditions. This indicates a real need to discover the histamine-independent pathways involved. Progress has been made recently in histamine-independent itch research with the discovery of the family of Mrgprs.

Mrgpr genes encode a family of orphan G protein-coupled receptors (GPCRs) consisting of more than 50 members in the mouse genome [2,163,164]. The expression of many Mrgprs, including MrgprA3 and MrgprC11, is found in subsets of small-diameter sensory neurons in DRG and trigeminal ganglia [2,163,164]. The human MrgprXs is also selectively expressed in DRG neurons [165]. The specific expression pattern of Mrgprs in primary sensory neurons indicates that these receptors play essential roles in sensation such as pain and itch. Mrgprs should be examined for contributions to cough. Besides the DRG, MrgprA3 and MrgprC11 are also expressed in the mouse nodose/vagus ganglion, which innervates the airway. With the discovery of specific ligands for MrgprX1 and MrgprC11, such as BAM8-22, the tussive role of Mrgprs can be quickly explored. For example, β-alanine activates MrgprD1* neurons which are histamine insensitive [166]. It would be interesting to know whether application of Mrgpr agonists such as β-alanine can cause cough. If so, are Mrgpr expression levels increased under chronic cough conditions?

Realizing the similarities between itch and cough might result in the expansion of the repertoire of tussive agents. Or working in the other direction, increase the number of pruritogens, which is very useful for chemical probing. Expanding the knowledge of cough by realizing the parallels and similarities to itch can lead to new therapies and treatments for both. This increase of knowledge and theory could eventually lead to enhancements in treatments of chronic itch and cough that could help the millions suffering every day.

Ethical approval
There are no unpublished experiments and data presented in this review article.

Abbreviations
DRG: Dorsal root ganglia; RARs: Rapidly adapting receptors; SARs: Slowly adapting receptors; CMH: C fibers classified as mechanical and heat responsive; CMHis+: Mechanically-insensitive C fibers that respond to histamine; PG2: Prostaglandin E2; CGRP: Calcitonin gene related peptide; TRPV1: Transient receptor potential vanilloid 1; GPCRs: G protein coupled receptors; PLC: Phospholipase C; DAG: Dicylglycerol; AD: Atopic dermatitis; SP: Substance P; NK1: Neurokinin T; NK: Neurokinin; CFA: Complete Freund’s adjuvant; ACE: Angiotensin converting enzyme; CNPC: Chronic nonproductive cough; BAL: Bronchoalveolar lavage; UNDW: Ultrasonically nebulised distilled water; 5-HT: Serotonin; PAR: Protease activated receptor; GRPR: Gastrin-releasing peptide receptor; GRP: Gastrin-releasing peptide; HBE: Human bronchial epithelial.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
PCL and XD wrote the manuscript. Both authors reviewed and approved the final manuscript.

Acknowledgements
The work was supported by grants from the NIH to X.D. (NS054791 and GM087369). X.D. is an Early Career Scientist of the Howard Hughes Medical Institute.

Received: 16 November 2012 Accepted: 8 February 2013
Published: 6 March 2013

References
1. Yosipovitch G, Duque MI, Fast K, Dawn AG, Coghill RC. Scratching and noxious heat stimuli inhibit itch in humans: a psychophysical study. Br J Dermatol 2007, 156(4):629–634.
2. Zylka MJ, Dong X, Southwell AL, Anderson DJ. Atypical expansion in mice of the sensory neuron-specific Mrg G protein-coupled receptor family. Proc Natl Acad Sci USA 2003, 100(17):10043–10048.
3. Widdicombe JG. Afferent receptors in the airways and cough. Respir Physiol 1998, 114(1):15.
4. Nairn J, Belvisi MG. Modulation of sensory nerve function and the cough reflex: understanding disease pathogenesis. Pharmacol Ther 2009, 124(3):354–375.
5. Karlsson JA, Sant’Ambrogio G, Widdicombe J. Afferent neural pathways in cough and reflex bronchoconstriction. J Appl Physiol 1988, 65(3):1007–1023.
6. Paus R, Schmelz M, Biro T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2005, 116(5):1174–1186.
7. Undem BJ, Chuaychoo B, Lee MG, Weinreich D, Myers AC, Kollarik M: Subtypes of vagal afferent C-fibres in guinea-pig lungs. J Physiol 2004, 556(Pt 3):905–917.

8. Brozmanova M, Ru F, Surdenikova L, Mazurova L, Taylor-Clark T, Kollarik M: Preferential activation of the vagal nodose nociceptive subtype by TRPA1 agonists in the guinea pig esophagus. Neurogastroenterol Motil 2011, 23(6):437–45.

9. Graham DT, Goodell H, WOLFF HG: Neural mechanisms involved in itch, itchy skin, and tickle sensations. J Clin Invest 1951, 30(1):37–49.

10. Shelley WB, Arthur RP: The neurohistology and neurophysiology of the itch sensation in man. Arch Histol Anat 1973, 36(3):296–325.

11. Ringkamp M, Scheipers RJ, Shimada SG, Johanek LM, Hartke TV, Borzan J, Shim B, LaMotte RH, Neyer RA: A role for nociceptive, myelinated nerve fibers in itch sensation. J Neurosci 2011, 31(42):14841–14849.

12. Lue T, Undem BJ: Neuropolyticity in vagal afferent neurons involved in cough. Pulm Pharmacol Ther 2011, 24(3):276–279.

13. Canning BJ, Mori N, Mazzone SB: Vagal afferent nerves regulating the cough reflex. Respir Physiol Neurobiol 2006, 152(3):223–242.

14. Tatar M, Sant Ambrogio G, Sant Ambrogio F: Laryngeal and tracheobronchial cough in anesthetized dogs. J Appl Physiol 1994, 76(6):2672–2679.

15. Fox AJ, Barnes PJ, Dray A: C-receptors for itch in human skin. Respir Physiol 2001, 125(3):267–281.

16. Scheilegie ES: Functional morphology and physiology of slowly adapting pulmonary stretch receptors. Anat Rec A Discov Mol Cell Evol Biol 2003, 270(1–2):12–10.

17. Canning BJ, Chou YL: Cough sensors. I. Physiological and pharmacological properties of the afferent nerves regulating cough. Handb Exp Pharmacol 2009, 187(187):23–47.

18. Canning BJ: Functional implications of the multiple afferent pathways regulating cough. Pulm Pharmacol Ther 2011, 24(3):295–299.

19. Canning BJ, Mazzone SB, Meek SM, Mori N, Reynolds SM, Undem BJ: Identification of the tracheal and laryngeal afferent neurones mediating cough in anaesthetised guinea-pigs. J Physiol 2004, 557(Pt 2):543–558.

20. Kwong K, Carr R, Gibbard A, Savage TJ, Singh K, Jing J, Meek S, Undem BJ: Voltage-gated sodium channels in nociceptive versus non-nociceptive nodose vagal sensory neurones innervating guinea pig lungs. J Physiol 2008, 586(5):1321–1336.

21. Namer B, Dray A: An in vitro study of the properties of single vagal afferents innervating guinea-pig airways. J Physiol 1993, 469(1):33–45.

22. Widdicombe JG: Receptors in the trachea and bronchi of the cat. J Physiol 1954, 123:171–104.

23. Widdicombe JG: Functional morphology and physiology of pulmonary rapidly adapting receptors (RARs). Anat Rec A Discov Mol Cell Evol Biol 2003, 270(1–2):12–10.

24. Torebjork HE, Sant Ambrogio G, Sant Ambrogio F, Mathew OP: Reflex responses to capsaicin: intraesophageal, aerosol, and intratracheal administration. J Appl Physiol 1989, 67(4):1428–1437.

25. Hunter DD, Undem BJ: Identification and substance P content of vagal afferent neurones innervating the epithelium of the guinea pig trachea. Am J Respir Crit Care Med 1999, 159(6):1943–1948.

26. LaVinka and Dong 2010.

27. Park GH, Lee H, Anderson DJ, Simon ML, Basbaum AI, Han SK: TRPV1-expressing primary afferent nerves generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci USA 2009, 106(27):11330–11335.

28. Laude EA, Higgins KS, Morice AH: Nitric oxide contributes to substance P-induced increases in lung rapidly adapting receptor activity in guinea-pigs. J Physiol 1997, 503 (Pt 3):363–645.

29. Mazeone SB, Mori N, Canning BJ: Synergistic interactions between airway afferent nerve subtypes regulating the cough reflex in guinea-pigs. J Physiol 2005, 569(Pt 5):559–573.

30. Ross SE: Pain and itch: insights into the neural circuits of aversive sensations evoked by punctate cutaneous application of capsaicin, histamine and cowhage. Pain 2009, 144(1):216–256.

31. Shim WS, Tak MH, Lee MH, Kim M, Kim M, Koo JY, Lee CH, Kim M, Oh U: TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci 2007, 27(9):2331–2337.

32. Patel KN, Liu Q, Meeker S, Undem BJ, Dong X: A TRPV1 modulator, is required for histamine-dependent and -independent itch. PloS One 2011, 6(3):e19559.

33. Imamura N, Park GH, Lee H, Anderson DJ, Simon ML, Basbaum AI, Han SK: TRPV1-expressing primary afferent nerves generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci USA 2009, 106(27):11330–11335.

34. Widdicombe JG, Chou YL: Cough sensors. I. Physiological and pharmacological properties of the afferent nerves regulating cough. Handb Exp Pharmacol 2009, 187(187):23–47.

35. Canning BJ: Functional implications of the multiple afferent pathways regulating cough. Pulm Pharmacol Ther 2011, 24(3):295–299.

36. Canning BJ, Mazzone SB, Meek SM, Mori N, Reynolds SM, Undem BJ: Identification of the tracheal and laryngeal afferent neurones mediating cough in anaesthetised guinea-pigs. J Physiol 2004, 557(Pt 2):543–558.

37. Kwong K, Carr R, Gibbard A, Savage TJ, Singh K, Jing J, Meek S, Undem BJ: Voltage-gated sodium channels in nociceptive versus non-nociceptive nodose vagal sensory neurones innervating guinea pig lungs. J Physiol 2008, 586(5):1321–1336.

38. Namer B, Carr R, Johanek LM, Schmelz M, Handwerker HO, Ringkamp M: Separate peripheral pathways for pruritus in man. J Neurophysiol 2008, 100(4):2062–2069.

39. Sant Ambrogio G, Widdicombe J: Reflexes from airway rapidly adapting receptors. Respir Physiol 2001, 125(1):33–45.

40. Winkelmann RK: Some sensory nerve endings in the skin: preliminary report on the morphology of cutaneous sensation. AMA Arch Derm 1955, 71(3):373–378.

41. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjerkt HE: Specific C-receptors for itch in human skin. J Neurosci 1997, 17(20):8003–8008.

42. Toth-Kasa I, Janco G, Bogner A, Husz S, Obal FJ: Capsaicin prevents histamine-induced itching. J Clin Pharmacol Res 1986, 60(2):163–169.

43. Ma C, Nie H, Gu Q, Sikand P, Lamotte RH: In vivo responses of cutaneous C-meansensitive neurones in mouse to punctuate chemical stimuli that elicit itch and nociceptive sensations in humans. J Neurophysiol 2012, 107(1):357–363.

44. Mazzone SB, Undem BJ: Cough sensors. V. Pharmacological modulation of cough sensitivity in guinea-pigs. Handb Exp Pharmacol 2009, 187(187):199–127.

45. Forberg K, Karlsson JA, Theodorsson E, Lundberg JM, Persson CG: Cough and bronchoconstriction mediated by capsaicin-sensitive sensory neurones in the guinea-pig. Pulm Pharmacol 1988, 1(1):33–39.

46. Ricco MM, Kummer W, Biglari B, Myers AC, Undem BJ: Interangionic segregation of distinct vagal afferent fibre phenotypes in guinea-pig airways. J Physiol 1996, 496 (Pt 2):P251–P31.
56. Bolser DC, Aziz SM, Chapman RW: Ruthenium red decreases capsaicin and citric acid-induced cough in guinea pigs. Neurosci Lett 1991, 126(1):131–133.

57. Jia Y, McLeod RL, Wang X, Parra LE, Egan RW, Hey JA: Anandamide induces cough in conscious guinea pigs through V1R receptors. Br J Pharmacol 2002, 137(6):831–836.

58. Hirvann A, Chong HH, Bautista DM, Julius D: TRP channel activation by reversible covalent modification. Proc Natl Acad Sci USA 2006, 103(11):1954–1958.

59. Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Crawf BT, Patapoutian A: Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature 2007, 445(7127):541–545.

60. Liu Q, Taz G, Sundenikova L, Kim S, Patel KN, Aim R, Fu G, Yuan W, Weng HJ, Geng Y, Undem BJ, Kollman M, Chen ZF, Anderson DJ, Dong X: Sensory neuron-specific GPCLR Mrgggs are itch receptors mediating chloroquine-induced pruritus. Cell 2009, 139(3):1335–1346.

61. Wilson SR, Gerhold KA, Bifolck-Fisher A, Liu Q, Patel KN, Dong X, Bautista DM: TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat Neurosci 2011, 14(5):595–602.

62. Liu J, J Rib: Oxidative stress initiates itch via activation of transient receptor potential subtype akyrin 1 in mice. Neuropsy Bull 2012, 28(2):65–154.

63. Bickers DR, Athar M: Neuropeptides and plasma leakage in the skin. J Dermatol Sci 2004, 37(2):123–135.

64. Briers DR, Athar M: Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol 2006, 126(12):2565–2575.

65. Nassenstein C, Kwong K, Taylor-Clark T, Kollarik M, Macglashan D, Braun A, Undem BJ: Expression and function of the ion channel TRPA1 in vagal afferent nerves innervating mouse lungs. J Physiol 2008, 586(15):1593–1604.

66. Hassass BF, Sinha M, Von Hehn CA, Esclaire J, Cohn J, Jovit SE: TRPA1 is a major oxidant sensor in murine airway sensory neurons. J Clin Invest 2008, 118(5):1899–1910.

67. Belviti MG, Stretton CD, Barnes PJ: Bombesin-induced bronchoconstriction in the guinea pig model of action. J Pharmacol Exp Ther 1991, 258(1):36–41.

68. Birell MA, Belviti MG, Grace M, Sadofsky L, Fanau S, Hele DJ, Maher SA, Freund-Michel V, Morice AH: TRPA1 agonists evoke coughing in guinea pig. Arch Dermatol Res 2008, 300(1):1042–1047.

69. Brozmarova M, Mazurova L, Fu R, Tatar M, Kollarik M: Comparison of TRPA1 versus TRPV1-mediated cough in guinea pigs. Eur J Pharmacol 2012, 689(1–2):211–218.

70. Andre E, Campi B, Materazzi S, Trevissi M, Amadesi S, Massi D, Cermoin C, Vaksman N, Nasini R, Civelli M, Bardi B, Poole DP, Bunnitt NW, Geppetti P, Patacchini R: Cigarette smoke-induced neurogenic inflammation is mediated by alpha, beta-unsaturated aldehydes and the TRPA1 receptor in rodents. J Clin Invest 2008, 118(5):2574–2582.

71. Andre E, Gatti R, Trevissi M, Preti D, Baraldi PG, Patacchini R, Geppetti P: Transient receptor potential akyrin 1 is novel target for pro-tussive agents. Br J Pharmacol 2009, 158(16):1621–1628.

72. Holzer P: Neurogenic vasodilation and plasma leakage in the skin. Gen Pharmacol 1999, 30(15):11.

73. Hosogi M, Schmelz M, Miyachi Y, Ikoma A: Bradykinin is a potent pruritogen in atopic dermatitis: a switch from pain to itch. Pain 2006, 126(1–3):16–23.

74. Hagermark O, Hokfelt T, Pernow B: Anandamide induces cough in guinea pigs, and activates mast cells, mast cell degranulation, and increases plasma levels in patients with persistent cough. Respir Res 2011, 8(25):431–438.

75. Liang J, He Y, Ji W: Bradykinin-evoked coughing responses in complete Freund's adjuvant-inflamed skin through activation of B1 receptor. Exp Biol Med (Maywood) 2012, 237(3):318–326.

76. Costa R, Manjavachc MN, Motta EM, Marotta DM, Juliano L, Torres HA, Piresque JB, Calixto JB: The role of kinin B1 and B2 receptors in the scratching behaviour induced by proteinase-activated receptor-2 agonists in mice. Br J Pharmacol 2010, 159(4):888–897.

77. Threepieders K: Adverse reactions in the skin from anti-hypertensive drugs. Dan Med Bull 1987, 34(Suppl 1):3–5.

78. Stockelings UM, Attur, M, Wallisclager T, Wehlschutz S, Henz BM: Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol 2001, 81(5):321–325.

79. Baumgarten CR, Lehmkuhl B, Hennings BR, Brunne T, Dorov P, Schilling W, Kunkel G: Bradykinin and other inflammatory mediators in BAL-fluid from patients with active pulmonary inflammation. Agents Actions Suppl 1992, 38 (Pt 3):475–481.

80. Kajekar R, Proud D, Myers AC, Meeker SN, Undem BJ: Characterization of vagal afferent subtypes stimulated by bradykinin in guinea pig trachea. J Pharmacol Exp Ther 1999, 289(2):628–637.

81. Fuller LW, Dixon CM, Cuss FM, Barnes PJ: Bradykinin-induced bronchoconstriction in humans. Med Pr 1998, 135(11):176–180.

82. Choudry NB, Fuller RW, Pride NB: Sensitivity of the human cough reflex: effect of inflammatory mediators prostaglandin E2, bradykinin, and histamine. Am Rev Respir Dis 1989, 140(11):137–141.

83. Krstev E, Jarrott B, Lawrence AJ: Bradykinin B2 receptors in nodose ganglia of rat and human. Eur J Pharmacol 1998, 348(2–3):175–180.

84. Fox AJ, Laloo LG, Belvisi MG, Bernaggi M, Chung KF, Barnes PJ: Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med 1996, 2(7):814–817.

85. Kang DS, Lee-Sundberg LH: Negative and positive regulatory epitopes in the C-terminal domains of the human B1 and B2 bradykinin receptor subtypes determine receptor coupling efficacy to G(q/11)-mediated (correction of G9/11-mediated) phospholipase Cbeta activity. Mol Pharmacol 2002, 61(2):282–288.

86. Lee MG, Kollarik M, Cuayacho B, Undem BJ: Ionotropic and metabotropic receptor mediated airway sensory nerve activation. Pulm Pharmacol Ther 2004, 17(6):355–360.

87. Botchkarev VA, Eichmueller S, Peters EM, Pietsch P, Johannson O, Maurer M, Paus R: A simple immunofluorescence technique for simultaneous visualization of mast cells and nerve fibers reveals selectivity and hair cycle-dependent changes in mast cell–nerve fiber contacts in murine skin. Arch Dermatol Res 1997, 289(2):292–302.

88. Boulou LP, Milot J, Bouter M, St Georges F, Laviolette M: Airway inflammation in nonasthmatic subjects with chronic cough. Am J Respir Crit Care Med 1994, 149(Pt 1):482–489.

89. McGaney LP, Forsythe P, Heaney LG, MacMahon J, Ennis M: Bronchoalveolar lavage findings in patients with chronic nonproductive cough. Eur Respir J 1999, 13(1):59–65.

90. Rao KN, Brown MA: Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann N Y Acad Sci 2008, 1143:83–104.

91. Simone DA, Ngeow JY, Whitehouse J, Becerra-Cabal L, Puttermann GJ, LaMotte RH: The magnitude and duration of itch produced by intracutaneous injections of histamine. Samatosens Res 1987, 5(2):81–92.

92. Skand P, Shimada SG, Green BG, LaMotte RH: Sensory responses to injection and punctate application of capsaicin and histamine to the skin. Pain 2011, 152(11):2485–2494.

93. Akiyama T, Merrill AW, Zanotto K, Castens MJ, Castens E: Scratching behavior and Fos expression in superficial dorsal horn elicited by protease-activated receptor agonists and other itch mediators in mice. J Pharmacol Exp Ther 2009, 329(5):945–951.

94. Andrew D, Craig AD: Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001, 4(11):72–77.

95. Simons FE, Simons KJ: Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011, 128(6):1339–1350.

96. Riley JF, West GB: The presence of histamine in tissue mast cells. J Physiol 1953, 120(4):528–537.
104. Hill SJ, Ganelin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, Haas HL. International Union of Pharmacology. XII. Classification of histamine receptors. Pharmaco 1997, 49(3):253–278.

105. Davies MC, Greaves MW. Sensory responses of human skin to synthetic histamine analogues and histamine. Br J Clin Pharmacol 1980, 9(5):461–465.

106. Bakker RA, Timmerman H, Leurs R. Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin Allergy Immunol 2002, 17:27–64.

107. Han SK, Mancino V, Simon M. Phospholipase Cbeta 3 mediates the scratching response activated by the histamine H1 receptor on C-fiber nociceptive neurons. Neuron 2006, 52(4):691–703.

108. Kim BM, Lee SH, Shin WS, Oh U. Histamine-induced Ca(2+)- influx via the PLAC2/lipoygenase/TYRO1 pathway in rat sensory neurons. Neurotox Lett 2004, 36(1):159–162.

109. Ikoma A, Rukwied R, Stander S, Steinhoff M, Miyachi Y, Schmelz M. Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol 2003, 139(11):1455–1458.

110. Bell JK, McQueen DS, Rees JL. Histamine H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol 2004, 142(2):374–380.

111. Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Invest Dermatol 2010, 130(4):1023–1033.

112. Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, Thurmond RL. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007, 119(1):176–183.

113. Undem BJ, Weinreich D. Electrophysiological properties and chemosensitivity of guinea pig nocod mighty ganglion neurons in vitro. J Auton Nerv Syst 1993, 44(1):17–33.

114. Lee LY, Morton RF. Histamine enhances vagal pulmonary C-fiber responses to capsaicin and lung inflation. Respir Physiol 1993, 93(1):83–96.

115. Lai YL, Lin TY. Mast cells in citric acid-induced cough of guinea pigs. Tox Appl Pharmacol 2005, 202(1):18–24.

116. Birring SS, Parker D, Brightling CE, Bradding P, Wardlaw AJ, Pavord ID. Chemosensitivity of guinea pig nodose ganglion neurons in vitro. Am J Respir Cell Mol Biol 2002, 26(2):159–162.

117. Brightling CE, Ward K, Wolttmann G, Bradding P, Sheller JR, Drsowski R, Pavord ID. Induced sputum inflammatory mediator concentrations in chronic cough. Am J Respir Crit Care Med 2004, 169(1):15–19.

118. Konig P, Krain P, Krafte G, Umer W. Serotonin increases cilia-driven particle transport via an acetylcholine-independent pathway in the mouse trachea. Plu 09, 43(6):e598.

119. Sun YG, Chen ZF. Atopy. Molecular cloning of a proteinase-activated receptor-2-activating receptor with endings in the intrapulmonary airways of dogs. J Physiol 2009, 587(Pt 3):535–5362.

120. Kushnir-Sukhov NM, Brown JM, Wu Y, Kirinzenbaum A, Metcalfe DD. Human mast cells are capable of serotonin synthesis and release. J Allergy Clin Immunol 2007, 119(4):498–499.

121. Klein A, Carstens MI, Carstens E. Facial injections of pruritogens or algogens elicit distinct behavior responses in rats and excite overlapping populations of primary sensory and trigeminal subcortical caudalis neurons. J Neurophysiol 2011, 106(3):1078–1088.

122. Akiyama T, Carstens MI, Carstens E. Enhanced scratching evoked by PAR-2 agonist and 5-HT but not histamine in a mouse model of chronic dry skin itch. Pain 2010, 151(2):378–383.

123. Huang J, Li G, Xiang J, Yin D, Chi R. Immunohistochemical study of serotonin in lesions of psoriasis. Int J Dermatol 2004, 43(6):408–411.

124. Huang J, Li G, Xiang J, Yin D, Chi R. Immunohistochemical study of serotonin in lesions of chronic eczema. Int J Dermatol 2004, 43(10):723–726.

125. Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjörk HE. Handwerker HO. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol 2003, 89(5):2441–2448.

126. Yamaguchi T, Nagawa T, Satoh M, Kurashiy V. Itch-associated response induced by intradermal serotonin through 5-HT2 receptors in mice. Neuroreport 1999, 10(5):137–139.

127. Bonnet T, Manet E. Anaesthesia outside the operating room: conflicting strategies? Curr Op Anesth Analg 2008, 21(4):478–479.

128. Coleridge HM, Coleridge JC, Schultz HD. Afferent pathways involved in reflex regulation of airway smooth muscle. Pharmacol Ther 1989, 42(1):1–83.

129. Coleridge HM, Coleridge JC. Impulse activity in afferent vagal C-fibres with endings in the intrapulmonary airways of dogs. Respir Physiol 1977, 30:125–142.

130. Peters JA, Malone HM, Lambert JJ. An electrophysiological investigation of the properties of 5-HT3 receptors of rabbit nodose ganglion neurons in culture. Br J Pharmacol 1993, 110(26):655–676.

131. Malone HM, Peters JA, Lambert JJ. Physiological and pharmacological properties of 5-HT3 receptors—a patch clamp-study. Neuropeptides 1991, 19(Suppl):25–30.

132. Honig H. Pharmacological aspects of visceral sensory receptors. Prog Brain Res 1986, 67:149–162.

133. Chaukchoo B, Lee MG, Kollarik M, Undem BJ. Effect of 5-hydroxytryptamine on vagal C-fiber subtypes in guinea pig lungs. Pulm Pharmacol Ther 2005, 18(4):269–276.

134. Potoncez C, Meeker S, Undem BJ. Activation of mouse bronchopulmonary C-fibres by serotonin and allergen-ovalbumin challenge. J Pharmacol 2012, 590(Pt 2):5449–5459.

135. Ossovskaia VS, Burnett NW. Proteinase-activated receptors: contribution to physiology and disease. Physiol Rev 2004, 84(2):759–821.

136. Hullenberg MD, Compton JR. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 2002, 54(2):203–217.

137. Nystedt S, Emilsson K, Wahnstedt C, Sundell J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 1994, 91(20):9208–9212.

138. Shimada SG, Shimada KA, Collins JG. Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2. Eur J Pharmacol 2006, 530(3):281–283.

139. Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007, 448(7150):703–707.

140. Zhu Y, Wang XR, Peng C, Xu JG, Liu X, Wu L, Zhou QG, Liu JY, Li FQ, Pan YH, You BM, Hu JH. Induction of leukotriene B4 (prostaglandin E2) release from keratinocytes by proteinase-activated receptor-2-activating peptide in ICR mice. Int Immunopharmacol 2009, 9(11):1352–1368.

141. Steinhoff M, Verghienne N, Young SH, Tognotto M, Amadesi S, Ennes HS, Trevisani M, Hollenberg MD. Evidence for the role of neurogenic inflammation in lesions of chronic eczema. J Invest Dermatol 2009, 62(9):1515–1518.

142. Costa R, Marotta DM, Manjavich MN, Fernandes ES, Lima-Garcia JF, Paszcuk AF, Obata K, Yamanaka H, Noguchi K. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Allergy Clin Immunol 2003, 111(3):713–722.

143. Grant AD, Cottrell GS, Amadesi S, Trevisani M, Nicoletti P, Materazzi S, Ather C, Cencuc N, Zamponi GW, Saustia-Cruz F, Lopez CB, Joseph MK, Levine JD, Lidtke W, Vanner S, Verghiele N, Geppetti P, Maffei P, Mayer EA, Burnett NW. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000, 6(2):151–158.

144. Costa R, Marotta DM, Manjavich MN, Fernandes ES, Lima-Garcia JF, Paszcuk AF, Quntiao NL, Juliano L, Brain SD, Calixto JB. Evidence for the role of neurogenic inflammation components in trypan-elicited scratching behaviour in mice. Br J Pharmacol 2008, 154(5):1094–1103.
150. Ricciardolo FL, Steinhoff M, Amadesi S, Guerini R, Toognotto M, Trevisani M, Creminon C, Bertrand C, Burnett NW, Fabbri LM, Salvadori S, Geppetti P: Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways. Am J Respir Crit Care Med 2000, 161(5):1672–1680.

151. Schmollin F, Amadesi S, Dabbagh K, Lewis DE, Knot P, Burnett NW, Gater PR, Geppetti P, Bertrand C, Stevens ME: Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 2002, 169(9):5315–5321.

152. Miccio D, Hollenberg MD, Burnett NW, Papi A, Braccioni F, Boschetto P, Rea F, Zuin A, Geppetti P, Saretta M, Maestrelli P, Fabbri LM, Mapp CE: Expression of protease activated receptor-2 (PAR-2) in central airways of smokers and non-smokers. Thorax 2002, 57(2):146–151.

153. Gods TM, Fong B, Chow JM, Anderson GP, Frauman AG, Golde RG, Henry PJ, Carr MJ, Hamilton JR, Moffatt JD: A protective role for protease-activated receptors in the airways. Nature 1999, 398(6723):156–160.

154. Costello JF, Dunlop LS, Gardiner PJ: Characteristics of prostaglandin induced cough in man. Br J Clin Pharmacol 1985, 20(4):355–359.

155. Carr MJ, Schechter NM, Undem BJ: Trypsin-induced, neurokinin-mediated contraction of guinea pig bronchus. Am J Respir Crit Care Med 2000, 162(5):1662–1667.

156. Gatti R, Andre E, Amadesi S, Dinh TQ, Fischer A, Burnett NW, Harrison S, Geppetti P, Trevisani M: Protease-activated receptor-2 activation exaggerates TRPV1-mediated cough in guinea pigs. J Appl Physiol 2006, 101(2):506–511.

157. Amadesi S, Nie J, Vergnolle N, Cottrell GS, Grady EF, Trevisani M, Manni C, Geppetti P, McRoberts JA, Ennes H, Davis JB, Mayer EA, Burnett NW: Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci 2004, 24(18):4300–4312.

158. Liu Q, Weng HJ, Patel KN, Tang Z, Bai H, Steinhoff M, Dong X: The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci Signal 2011, 4(181):ra45.

159. Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF: Sensitization of pulmonary chemosensitive neurons by RF-amide-related peptides through the Galpha q/11 pathway. Proenkephalin A specific GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 2001, 106(5):619–632.

160. Han SK, Dong X, Hwang J, Zylka MJ, Anderson DJ, Simon MI: Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Galphai11 pathway. Proc Natl Acad Sci USA 2002, 99(23):14740–14745.

161. Shen SH, Strom P, Payza K, Dray A, Walker P, Ahmad S: β-alanine. J Neurosci 2012, 32(42):14532–14537.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit